“Effect of treatment with growth hormone in infertility”

The randomized single-blinded clinical trial comparing growth hormone effect versus placebo on Improving the outcome of pregnancy in infertile patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140818018842N14

Enrollment

105

Registered

2018-08-11

Start date

2016-04-20

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

poor ovarian response. Female infertility associated with anovulation

Interventions

Intervention 1: Intervention group 1: received Gonadotropin (Gonal-f 300 to 450 IU/day, subcutaneously, based on age and follicular count) from the third day of the cycle plus GnRH antagonist (Cetroti

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Sign the informed consent form Patients with poor ovarian response based on criteria provided by the Union embryology and infertility Europe 2011. Strong history of poor ovarian response (Having a maximum of three ovum after inducing ovulation protocols) Low score ovarian reserve (AFC less than 7, AMH less than 0.5-1.1 ng/ml)

Exclusion criteria

Exclusion criteria: Women with high levels of FSH (more than 20 IU/L) Women with a history of infertility due to known non poor ovarian resonce Women with diabetes (type I or II)

Design outcomes

Primary

Measure	Time frame
The follicle number obtained in the ART cycle. Timepoint: Before starting treatment, on day eighth of a cycle, 36 hours after injecting HCG. Method of measurement: Trans vaginal ultrasonography.	—

Secondary

Measure	Time frame
The number of metaphase II follicles achieved in the ART cycle. Timepoint: According embryologist report at ovum puncture. Method of measurement: Count of meta-phase II follicles in embryologist ward by microscopic observation.;The number of quality embryos obtained from the ART cycle. Timepoint: Third and fifth day after fertilization in the laboratory. Method of measurement: Report embryologists based grading A, B, C.;The number of positive pregnancy test. Timepoint: 14 days after embryo transfer. Method of measurement: BHCG over than 40 IU.;Successful clinical pregnancy. Timepoint: 6 to 8 weeks after embryo transfer. Method of measurement: Fetal Heart in Transvaginal ultrasonography.	—

Measure

Time frame

The number of metaphase II follicles achieved in the ART cycle. Timepoint: According embryologist report at ovum puncture. Method of measurement: Count of meta-phase II follicles in embryologist ward by microscopic observation.;The number of quality embryos obtained from the ART cycle. Timepoint: Third and fifth day after fertilization in the laboratory. Method of measurement: Report embryologists based grading A, B, C.;The number of positive pregnancy test. Timepoint: 14 days after embryo transfer. Method of measurement: BHCG over than 40 IU.;Successful clinical pregnancy. Timepoint: 6 to 8 weeks after embryo transfer. Method of measurement: Fetal Heart in Transvaginal ultrasonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefe Samaei

Tehran University of Medical Sciences

asamaei@razi.tums.ac.ir+98 21 84901

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026